DrugPatentWatch Database Preview
SUPRAX Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Suprax patents expire, and when can generic versions of Suprax launch?
Suprax is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms. and is included in eight NDAs. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has two patent family members in two countries.
The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefixime profile page.
US ANDA Litigation and Generic Entry Outlook for Suprax
A generic version of SUPRAX was approved as cefixime by AUROBINDO PHARMA LTD on April 14th, 2015.
Summary for SUPRAX
| International Patents: | 2 |
| US Patents: | 1 |
| Applicants: | 3 |
| NDAs: | 8 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 59 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,689 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SUPRAX |
| DailyMed Link: | SUPRAX at DailyMed |
Recent Clinical Trials for SUPRAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AIDS Healthcare Foundation | Phase 2 |
| University of California, Los Angeles | Phase 2 |
| University of Colorado, Denver | Phase 1 |
Pharmacology for SUPRAX
| Drug Class | Cephalosporin Antibacterial |
Synonyms for SUPRAX
| (-)-Cefixim |
| (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl}amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime) trihydrate |
| (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-(carboxymethyl)oxime)trihydrate |
| (6r,7r)-7-[-2-(2-amino-thiazol-4-yl)-2-carboxymethoxyimino-acetylamino]-8-oxo-3-vinyl-5-thia-1-aza-b |
| (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[[(2z)-2-(2-amino-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]Oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (E)-Cefixime |
| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, trihydrate, (6R-(6alpha,7beta(Z)))- |
| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-(2-amino-4-thiazolyl)((carboxymethoxy)imino)acetyl)amino)-3-ethenyl-8-oxo-, (6R,7R)- |
| 50C371 |
| 79350-37-1 |
| 7beta-{(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido}-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid |
| A13697 |
| AB00513842 |
| AB0073052 |
| AC-4350 |
| AKOS015854940 |
| AKOS015961135 |
| AT-7061 |
| BDBM84007 |
| BPBio1_000622 |
| BRD-K71059170-001-02-5 |
| BRD-K71059170-001-08-2 |
| BRN 6025058 |
| BSPBio_000564 |
| C04 |
| C06881 |
| CCG-220462 |
| Cefixim |
| Cefixima |
| Cefixima [Spanish] |
| CEFIXIME |
| Cefixime (JAN/USP/INN) |
| Cefixime [USAN:USP:INN:BAN:JAN] |
| Cefixime Anhydrous |
| Cefixime EP Impurity C (Cefixime 7-epimer) |
| Cefixime hydrate |
| Cefixime, 98% |
| Cefixime, Antibiotic for Culture Media Use Only |
| Cefiximum |
| Cefiximum [Latin] |
| Cefixoral |
| Cefspan |
| Cephoral |
| CFIX |
| CHEBI:472657 |
| CHEMBL1541 |
| cid_5362065 |
| CL 284,635 |
| CL 284635 |
| CL-284635 |
| CS-4820 |
| D00258 |
| DB00671 |
| Denvar |
| FK 027 |
| FK-027 |
| FR 17027 |
| FR-17027 |
| HMS2096M06 |
| HMS2234J21 |
| HMS3713M06 |
| HY-B1381 |
| LS-187248 |
| MLS002222332 |
| NCGC00179521-01 |
| Necopen |
| Oroken |
| Prestwick3_000462 |
| PubChem13762 |
| Q27290799 |
| s4596 |
| SCHEMBL24945 |
| SMR001307271 |
| SR-01000760706 |
| SR-01000760706-4 |
| Suprax (TN) |
| TC-070894 |
| Tricef |
| UNII-XZ7BG04GJX |
| Unixime |
| X-2622 |
| XZ7BG04GJX |
| ZINC12503147 |
US Patents and Regulatory Information for SUPRAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | SUPRAX | cefixime | CAPSULE;ORAL | 203195-001 | Jun 1, 2012 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Lupin Ltd | SUPRAX | cefixime | TABLET, CHEWABLE;ORAL | 065380-002 | Oct 25, 2010 | RX | No | No | Start Trial | Start Trial | Start Trial | ||||
| Lupin Pharms | SUPRAX | cefixime | FOR SUSPENSION;ORAL | 065129-001 | Feb 23, 2004 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Lupin Ltd | SUPRAX | cefixime | TABLET, CHEWABLE;ORAL | 065380-003 | Oct 25, 2010 | RX | No | Yes | Start Trial | Start Trial | Start Trial | ||||
| Lederle | SUPRAX | cefixime | FOR SUSPENSION;ORAL | 050622-001 | Apr 28, 1989 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Lupin Ltd | SUPRAX | cefixime | FOR SUSPENSION;ORAL | 202091-001 | Feb 20, 2013 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Lupin Ltd | SUPRAX | cefixime | TABLET, CHEWABLE;ORAL | 065380-001 | Oct 25, 2010 | RX | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SUPRAX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007119249 | Start Trial |
| Germany | 112007000920 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
